These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25643197)

  • 1. Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment.
    Rafouli-Stergiou P; Parissis JT; Farmakis D; Bistola V; Frogoudaki A; Vasiliadis K; Ikonomidis I; Paraskevaidis I; Kremastinos D; Filippatos G; Lekakis J
    J Cardiovasc Med (Hagerstown); 2017 Oct; 18(10):771-773. PubMed ID: 25643197
    [No Abstract]   [Full Text] [Related]  

  • 2. [Use of levosimendan in acute heart failure and its effect on renal function].
    Moyano AP; Hidalgo RL; Grande DB; Morales SC
    Nefrologia; 2009; 29(6):616-7. PubMed ID: 19936016
    [No Abstract]   [Full Text] [Related]  

  • 3. Levosimendan improves renal function in acute decompensated heart failure: cause and clinical application. Editorial to: "Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine by Yilmaz et al.".
    Damman K; Voors AA
    Cardiovasc Drugs Ther; 2007 Dec; 21(6):403-4. PubMed ID: 18030611
    [No Abstract]   [Full Text] [Related]  

  • 4. Levosimendan.
    Kamath SR; Jaykumar I; Matha S
    Indian Pediatr; 2009 Jul; 46(7):593-6. PubMed ID: 19638658
    [No Abstract]   [Full Text] [Related]  

  • 5. Medical support and surgery of the failing heart: levosimendan.
    Toller W; Knez I
    Scand J Surg; 2007; 96(2):121-4. PubMed ID: 17679353
    [No Abstract]   [Full Text] [Related]  

  • 6. Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long?
    Parissis JT; Farmakis D; Kremastinos DT
    Eur J Heart Fail; 2006 Mar; 8(2):215; author reply 218. PubMed ID: 16442844
    [No Abstract]   [Full Text] [Related]  

  • 7. Levosimendan: a new option in acute cardiac failure.
    Holley AD; Ziegenfuss M
    Emerg Med Australas; 2006; 18(5-6):505-9. PubMed ID: 17083641
    [No Abstract]   [Full Text] [Related]  

  • 8. [Levosimendan for treatment of heart failure].
    Yasumura Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():169-72. PubMed ID: 17571380
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure.
    Parissis JT; Adamopoulos S; Antoniades C; Kostakis G; Rigas A; Kyrzopoulos S; Iliodromitis E; Kremastinos D
    Am J Cardiol; 2004 May; 93(10):1309-12. PubMed ID: 15135713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the in vivo mechanism of action of levosimendan?
    MacGowan GA
    J Card Fail; 2005 Aug; 11(6):482; author reply 482-3. PubMed ID: 16105641
    [No Abstract]   [Full Text] [Related]  

  • 11. [Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?].
    Rasmussen T; Schmidt H
    Ugeskr Laeger; 2006 Jan; 168(3):261-5. PubMed ID: 16430807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Levosimendan in patients with decompensated heart failure.
    Rosa EM; Osório AP; Scopel L
    Arq Bras Cardiol; 2008 Aug; 91(2):119. PubMed ID: 18709265
    [No Abstract]   [Full Text] [Related]  

  • 13. [Levosimendan].
    Michels G; Herzig S; Hoppe UC
    Dtsch Med Wochenschr; 2005 Oct; 130(43):2444-6. PubMed ID: 16240243
    [No Abstract]   [Full Text] [Related]  

  • 14. Levosimendan and prostaglandin E1 for uptitration of beta-blockade in patients with refractory, advanced chronic heart failure.
    Berger R; Moertl D; Huelsmann M; Bojic A; Ahmadi R; Heissenberger I; Pacher R
    Eur J Heart Fail; 2007 Feb; 9(2):202-8. PubMed ID: 16859992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levosimendan displays anti-inflammatory effects and decreases MPO bioavailability in patients with severe heart failure.
    Adam M; Meyer S; Knors H; Klinke A; Radunski UK; Rudolph TK; Rudolph V; Spin JM; Tsao PS; Costard-Jäckle A; Baldus S
    Sci Rep; 2015 Apr; 5():9704. PubMed ID: 25867530
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study.
    Nieminen MS; Cleland JG; Eha J; Belenkov Y; Kivikko M; Põder P; Sarapohja T
    Eur J Heart Fail; 2008 Dec; 10(12):1246-54. PubMed ID: 18945637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure.
    Mueller T; Gegenhuber A; Haltmayer M
    Int J Cardiol; 2005 Oct; 104(3):355-6; author reply 357-8. PubMed ID: 15950299
    [No Abstract]   [Full Text] [Related]  

  • 18. Levosimendan: beyond its simple inotropic effect in heart failure.
    Antoniades C; Tousoulis D; Koumallos N; Marinou K; Stefanadis C
    Pharmacol Ther; 2007 May; 114(2):184-97. PubMed ID: 17363065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory effects of levosimendan in decompensated heart failure: impact on weight loss and anemia.
    Parissis JT; Farmakis D; Kremastinos DT
    Am J Cardiol; 2005 Apr; 95(7):923-4. PubMed ID: 15781038
    [No Abstract]   [Full Text] [Related]  

  • 20. Inotropic support in the NICU: ever more compounds in search of guidance? Commentary on J. Esch et al.: differential hemodynamic effects of levosimendan in a porcine model of neonatal hypoxia-reoxygenation (Neonatology 2012;101:192–200) and M.P. De Carolis et al.: levosimendan in two neonates with ischemic heart failure and pulmonary hypertension (Neonatology 2012;101:201–205).
    Thewissen L; Allegaert K
    Neonatology; 2012; 101(3):206-9. PubMed ID: 22067565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.